Vanna Chiarion Sileni - Division of Medical Oncology, General Hospital, 35100 Padua, Italy

基本信息

浏览量：93

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 30 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Paolo A. Ascierto,Milena Casula,Jenny Bulgarelli,Marina Pisano,Claudia Piccinini,Luisa Piccin,Antonio Cossu,Mario Mandalà,Pier Francesco Ferrucci,Massimo Guidoboni,Piotr Rutkowski,Virginia Ferraresi,

Zenodo (CERN European Organization for Nuclear Research)no. 1 (2024): 1-12

引用0浏览0WOSNATURE引用

33P Impact of prior treatment on baseline immune biomarkers and nivolumab + relatlimab (NIVO+RELA)-induced changes in the tumor microenvironment (TME) in patients (pts) with melanoma from RELATIVITY-020

P.A. Ascierto, H. Tang, S. Dolfi, M.S. Nyakas,I-M. Svane,E. Muñoz Couselo, J.J. Grob, C.A. Gomez-Roca,V. Chiarion Sileni, K. Peltola, J. Larkin, I. Melero,

Immuno-Oncology and Technology (2023): 100502

引用0浏览0引用

1083MO Brain metastases and survival evaluation in the SECOMBIT trial

P.A. Ascierto, M. Mandalà,P.F. Ferrucci, M. Guidoboni,P. Rutkowski,V. Ferraresi,A.M. Arance Fernandez,M. Guida, E. Maiello,H. Gogas, E. Richtig,M.T. Fierro,

Annals of Oncology (2023): S653-S653

引用0浏览0引用

Phase II study SECOMBIT (sequential combo immuno and target therapy study): 4-years OS data and preliminary biomarkers evaluation

P. A. Ascierto, M. Mandala,P. F. Ferrucci,M. Guidoboni, P. Rutkowski, V. Ferraresi,A. M. Arance Fernandez, M. Guida, E. Maiello,H. J. Gogas, E. Richtig, M. T. Fierro,

Annals of Oncologyno. 7 (2022): S1408-S1409

引用1浏览0引用

Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAF^V600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study

Reinhard Dummer,Paola Queirolo,Ana Maria Abajo Guijarro,Youyou Hu,Dao Wang,Sérgio Jobim Azevedo,Caroline Robert,Paolo A. Ascierto,V. Chiarion Sileni,Paolo Pronzato,Francesco Spagnolo, Karmele Mujika,

Journal of Clinical Oncologyno. 16_suppl (2022): 9515-9515

引用0浏览0引用

Pembrolizumab Versus Placebo After Complete Resection Of High-Risk Stage Ii Melanoma: Efficacy And Safety Results From The Keynote-716 Double-Blind Phase Iii Trial

J. Luke, P. Rutkowski,P. Queirolo,M. Del Vecchio,J. Mackiewicz,V. Chiarion Sileni,L. De La Cruzmerino, M. A. Khattak,D. Schadendorf,G. V. Long,P. A. Ascierto, M. Mandala,

ANNALS OF ONCOLOGY（2021）

引用31浏览0引用

LBA40 SECOMBIT: The best sequential approach with combo immunotherapy [ipilimumab (I) /nivolumab (N)] and combo target therapy [encorafenib (E)/binimetinib (B)] in patients with BRAF mutated metastatic melanoma: A phase II randomized study

P.A. Ascierto, M. Mandala, P.F. Ferrucci, P. Rutkowski, M. Guidoboni,A.M. Arance Fernandez, V. Ferraresi, E. Maiello, M. Guida,M. Del Vecchio, M.T. Fierro, P. Queirolo,

Annals of Oncology (2021): S1316-S1317

引用0浏览0引用

Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)